PROTEOME SCIENCES PLC

Board/Management Information • Sep 14, 2020

National Storage Mechanism | Additional information

RNS Number : 8237Y

Proteome Sciences PLC

14 September 2020

14 September 2020

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Chief Executive Officer

The Board of Proteome Sciences plc is pleased to announce that Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer and she will take up the position on September 15th, 2020. Dr Ian Pike remains a director of the Company as Chief Scientific Officer, having also fulfilled the role of Interim Chief Executive Officer until Dr Söhngen's appointment.

Dr. Söhngen has established a strong and successful career in the pharmaceutical industry both in the US and Europe. She was a co-founder of Paion AG which developed a clinical-stage asset for the treatment of stroke and subsequently delivered a novel anaesthetic that received FDA approval earlier this year. Dr. Söhngen was instrumental in the acquisition of UK listed CeNeS Pharmaceuticals plc by Paion AG. Dr. Söhngen has also held roles as CEO at Mologen AG and Convert Pharmaceuticals and most recently ran a pharmaceutical consultancy with a strong focus on supporting Chinese companies and investors trying to enter the European pharmaceuticals research and development market.

Proteome Sciences Chairman Christopher Pearce commented "The Board is delighted to appoint Dr, Mariola Söhngen as our new CEO where she will build on the strong foundations that have already been established.  Mariola's time as Chief Medical Officer at Paion together with  her  international experience and network  will bring major benefits to our business as we look to engage more broadly with new and existing clients in the US, Europe and to address the rapidly growing Asian markets."

Commenting on her appointment, Dr. Söhngen said "I am very much looking forward to working with the highly respected and committed team at Proteome Sciences. The company has established a unique position in Precision Medicine through its specialist services business and the range of TMT® and TMTpro™ chemical tags sold globally by Thermo Scientific. I am excited to work with the board to expand commercial activities and continue to develop the corporate strategy. From my involvement in stroke at Paion, I arrive at the company highly impressed with the quality of the Proteome Sciences' technology in particular the biomarker discovery capabilities in Precision Medicine and Diagnostics which are of ever-increasing importance and value in these challenging times. As CEO of Proteome Sciences I look forward to applying the broad experience gained from my previous interactions with a wide range of pharmaceutical companies to strengthen Proteome Sciences´ position in Precision Medicine and to drive shareholder value."

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dr. Mariola Gabriela Söhngen (aged 59) has held the following directorships or partnerships in the past five years:

Current	Previous
Dres. Söhngen Beteiligungs GmbH	PAION AG PAION Deutschland GmbH PAION Holdings UK Limited PAION UK Limited THERASCI Limited Vita 34 AG Mologen AG Convert Pharmaceuticals SA

For further information:

Proteome Sciences plc
Dr Ian Pike, Interim Chief Executive Officer	Tel: +44 (0)20 7043 2116
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Finance) Tony Quirke (Sales)	Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADZGMLGFGGGZZ